Breaking News Instant updates and real-time market news.

RTRX

Retrophin

$21.50

0.23 (1.08%)

17:02
03/01/17
03/01
17:02
03/01/17
17:02

Retrophin down 3.2% after plans for Phase 3 trial before sparsentan filing

  • 01

    Mar

RTRX Retrophin
$21.50

0.23 (1.08%)

11/11/16
LEER
11/11/16
NO CHANGE
LEER
Outperform
Retrophin agreement for RE-024 bodes well for approval in 2019, says Leerink
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.
11/21/16
LEER
11/21/16
NO CHANGE
LEER
Outperform
Retrophin DUET data reintroduces accelerated approval optionality, says Leerink
Leerink analyst Joseph Schwartz says full DUET Phase 2b results for Retrophin's sparsentan in focal segmental glomerulosclerosis presented at the American Society of Nephrology Kidney Week meeting look "very strong" in terms of the ability of the drug to produce modified partial remissions and even some complete remissions during the 8-week double blind period. The analyst believes the "strong data" provides the company with as good an argument as ever to discuss the potential of accelerated approval with the FDA, although he notes that predicting FDA is "tough." He reiterates an Outperform rating on the shares.
11/21/16
BMOC
11/21/16
NO CHANGE
BMOC
Retrophin price target raised to $46 from $40 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company provided data on its Sparsentan treatment that the analyst views as positive. Kim now sees a 55% chance that the drug will be approved, up from 45% previously. The analyst continues to believe that the FDA might not accept proteinuria as an endpoint, but sees "growing evidence for proteinuria as a surrogate to kidney survival." Kim keeps an Outperform rating on the stock.
12/15/16
JMPS
12/15/16
NO CHANGE
JMPS
Experts support quick approval of Retrophin sparsentan, says JMP Securities
JMP Securities analyst Liisa Bayko says the firm's survey of experts who participated in the Phase 2 study of Retrophin's sparsentan in focal segmental glomerulosclerosis "showed strong support for accelerated approval" of the drug. Bayko reiterates a $28 price target and an Outperform rating on the shares of Retrophin.

TODAY'S FREE FLY STORIES

FL

Foot Locker

$34.88

-12.82 (-26.88%)

12:26
08/18/17
08/18
12:26
08/18/17
12:26
Downgrade
Foot Locker rating change  »

Foot Locker downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

12:25
08/18/17
08/18
12:25
08/18/17
12:25
General news
FX Action: Risk-off? No, risk on. USD-JPY popped »

FX Action: Risk-off? No,…

CPN

Calpine

$14.87

1.365 (10.11%)

12:20
08/18/17
08/18
12:20
08/18/17
12:20
Options
Heavy trading in Calpine calls as shares rally »

Heavy trading in Calpine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$19.55

-0.07 (-0.36%)

12:19
08/18/17
08/18
12:19
08/18/17
12:19
Hot Stocks
U.S EEOC sues Macy's for disability discrimination »

The U.S. Equal Employment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

$NSD

NASDAQ Market Internals

12:17
08/18/17
08/18
12:17
08/18/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
08/18/17
08/18
12:16
08/18/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$62.36

0.35 (0.56%)

, XLU

Utilities SPDR

$54.48

0.3 (0.55%)

12:06
08/18/17
08/18
12:06
08/18/17
12:06
Technical Analysis
Technical View: S&P 500 edges above flatline, mid-session update »

The S&P 500 (SPX) was…

XLE

Energy Select Sector SPDR

$62.36

0.35 (0.56%)

XLU

Utilities SPDR

$54.48

0.3 (0.55%)

XLF

Financial Select Sector

$24.72

0.105 (0.43%)

XLK

Technology Select Sector SPDR

$57.33

0.2 (0.35%)

IYR

DJ US Real Estate Index Fund

$79.07

-0.7 (-0.88%)

XLP

Consumer Staples Sector SPDR

$55.25

-0.105 (-0.19%)

XLY

Consumer Discretionary Sector SPDR

$88.62

-0.07 (-0.08%)

SPY

SPDR S&P 500 ETF Trust

$243.52

0.43 (0.18%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$910.98

-15.98 (-1.72%)

, GOOGL

Alphabet Class A

$927.66

-16.61 (-1.76%)

12:04
08/18/17
08/18
12:04
08/18/17
12:04
Hot Stocks
Google launches new machine learning tool to track hate news »

In a blog post…

GOOG

Alphabet

$910.98

-15.98 (-1.72%)

GOOGL

Alphabet Class A

$927.66

-16.61 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 24

    Aug

FMAO

Farmers & Merchants

$55.58

-0.17 (-0.30%)

12:00
08/18/17
08/18
12:00
08/18/17
12:00
Hot Stocks
Farmers & Merchants board declares two-for-one stock split »

Farmers & Merchants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$117.19

-6.7905 (-5.48%)

, CPN

Calpine

$14.83

1.33 (9.85%)

12:00
08/18/17
08/18
12:00
08/18/17
12:00
General news
On The Fly: Top stock stories at midday »

Stocks opened in negative…

DE

Deere

$117.19

-6.7905 (-5.48%)

CPN

Calpine

$14.83

1.33 (9.85%)

GPS

Gap

$22.43

-0.255 (-1.12%)

ROST

Ross Stores

$53.33

-1.04 (-1.91%)

AMAT

Applied Materials

$43.12

-1.34 (-3.01%)

THC

Tenet

$14.04

1.385 (10.95%)

INFY

Infosys

$14.71

-1.22 (-7.66%)

FL

Foot Locker

$34.97

-12.73 (-26.69%)

FINL

Finish Line

$11.99

-0.17 (-1.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 18

    Aug

  • 23

    Aug

  • 06

    Sep

  • 06

    Sep

  • 22

    Nov

BC

Brunswick

$50.33

-0.995 (-1.94%)

12:00
08/18/17
08/18
12:00
08/18/17
12:00
Options
Call buyers in Brunswick as shares fall »

Call buyers in Brunswick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

FL

Foot Locker

$34.98

-12.7201 (-26.67%)

11:59
08/18/17
08/18
11:59
08/18/17
11:59
Downgrade
Foot Locker rating change  »

Foot Locker downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

RDUS

Radius Health

$35.42

-1.01 (-2.77%)

11:58
08/18/17
08/18
11:58
08/18/17
11:58
Hot Stocks
Biotech Growth acquires 60,000 more shares of Radius Health »

Biotech Growth NV…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

CVNA

Carvana

$15.12

-0.06 (-0.40%)

11:54
08/18/17
08/18
11:54
08/18/17
11:54
Hot Stocks
Breaking Hot Stocks news story on Carvana »

Carvana drops 3% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

CVNA

Carvana

$15.12

-0.06 (-0.40%)

11:53
08/18/17
08/18
11:53
08/18/17
11:53
Periodicals
Carvana mentioned cautiously by Copperfield Research »

Copperfield Research, in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

AMAT

Applied Materials

$43.12

-1.34 (-3.01%)

11:51
08/18/17
08/18
11:51
08/18/17
11:51
Hot Stocks
Applied Materials CEO says technological shifts in industries to drive growth »

The CEO says has a good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$34.76

-12.94 (-27.13%)

11:50
08/18/17
08/18
11:50
08/18/17
11:50
Recommendations
Foot Locker analyst commentary  »

Foot Locker comp outlook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

11:50
08/18/17
08/18
11:50
08/18/17
11:50
General news
Fed's Kaplan sees GDP growth a little above 2% for 2017 »

Fed's Kaplan sees…

AMZN

Amazon.com

$960.57

-17.61 (-1.80%)

, ATVI

Activision Blizzard

$61.37

-1.52 (-2.42%)

11:49
08/18/17
08/18
11:49
08/18/17
11:49
Periodicals
Twitch acquires video indexing platform Clipmine, TechCrunch reports »

Twitch has acquired video…

AMZN

Amazon.com

$960.57

-17.61 (-1.80%)

ATVI

Activision Blizzard

$61.37

-1.52 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 23

    Aug

  • 24

    Aug

  • 24

    Aug

  • 05

    Sep

  • 07

    Sep

FL

Foot Locker

$34.82

-12.88 (-27.00%)

11:45
08/18/17
08/18
11:45
08/18/17
11:45
Downgrade
Foot Locker rating change  »

Wells doubts investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

AMAT

Applied Materials

$43.12

-1.34 (-3.01%)

11:42
08/18/17
08/18
11:42
08/18/17
11:42
Hot Stocks
Applied Materials CEO says much less volatility in chip sector »

The Applied Materials CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$34.94

-12.76 (-26.75%)

, NKE

Nike

$55.19

-2.27 (-3.95%)

11:41
08/18/17
08/18
11:41
08/18/17
11:41
Recommendations
Foot Locker, Nike, adidas analyst commentary  »

Foot Locker price target…

FL

Foot Locker

$34.94

-12.76 (-26.75%)

NKE

Nike

$55.19

-2.27 (-3.95%)

ADDYY

adidas

$111.98

-1.52 (-1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 03

    Oct

  • 04

    Oct

NBL

Noble Energy

$23.44

0.415 (1.80%)

11:40
08/18/17
08/18
11:40
08/18/17
11:40
Options
Notable put spread in Noble Energy »

Notable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

ABCO

The Advisory Board

$51.05

-0.8 (-1.54%)

11:35
08/18/17
08/18
11:35
08/18/17
11:35
Options
Advisory Board put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTNB

root9B Technologies

$0.60

-0.1665 (-21.72%)

11:30
08/18/17
08/18
11:30
08/18/17
11:30
Hot Stocks
Breaking Hot Stocks news story on root9B Technologies »

root9B Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.